We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Icosavax Inc | NASDAQ:ICVX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.31 | 15.15 | 15.31 | 0 | 01:00:00 |
From Jul 2022 to Jul 2024
Guggenheim 4th Annual Immunology and Neurology Conference
Jefferies London Healthcare Conference
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.icosavax.com. The webcast replays will be available following the conclusion of the presentations for approximately 90 days.
About Icosavax
Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), as well as programs in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza. Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle.
For more information, visit www.icosavax.com.
Media Contact: Jessica Yingling, Ph.D. Little Dog Communications Inc. jessica@litldog.com858.344.8091
Investor Contact:Laurence WattsGilmartin Group, LLClaurence@gilmartinir.com619.916.7620
1 Year Icosavax Chart |
1 Month Icosavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
